Beta1-adrenoceptor blockade mitigates excessive norepinephrine release into cardiac interstitium in mitral

Gerald H Hankes1, Jeffrey L Ardell, José Tallaj

  • 1Auburn University of Veterinary Medicine, Auburn, Alabama, USA.

Insights

Beta-blocker therapy in mitral regurgitation (MR) dogs reduces norepinephrine release from cardiac neurons. This attenuation of sympathetic nervous system activity may offer benefits without compromising early left ventricular (LV) function.

Area of Science:

  • Cardiovascular Physiology
  • Neurocardiology
  • Pharmacology

Background:

  • Mitral regurgitation (MR) increases norepinephrine (NE) and epinephrine (EP) release into myocardial interstitial fluid (ISF), potentially supporting left ventricular (LV) function via beta-adrenergic receptor (AR) activation.
  • However, neuronal beta-AR activation may paradoxically increase catecholamine release, risking functional decline.

Purpose of the Study:

  • To investigate the hypothesis that beta-receptor blockade (beta-RB) mitigates excessive catecholamine release from cardiac adrenergic neurons in dogs with MR.
  • To assess the impact of beta-RB on ISF NE and EP levels and LV function during MR.

Main Methods:

  • In vivo microdialysis was employed in open-chest anesthetized dogs subjected to MR for 4 weeks, with or without metoprolol succinate treatment, and in control dogs.
  • Measurements included ISF NE and EP release, fractional shortening, heart rate, and LV pressure changes (+dP/dt) following stellate ganglion stimulation.

Main Results:

  • Fractional shortening increased similarly in MR and MR + beta-RB groups.
  • Stellate-stimulated NE release into ISF was significantly attenuated in MR + beta-RB dogs compared to MR dogs.
  • Stellate-stimulated ISF EP increases did not differ across groups; heart rate response was attenuated in MR + beta-RB dogs.

Conclusions:

  • Beta-receptor blockade attenuates ISF NE release from cardiac neurons in MR.
  • Early LV functional adaptation to MR is not dependent on excessive ISF NE.
  • Beta1-RB may offer benefits by reducing excessive sympathetic efferent NE release while preserving early LV adaptation.

Related Concept Videos

Mitral Regurgitation III: Medical Management01:25

Mitral Regurgitation III: Medical Management

Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Mitral Regurgitation I: Introduction01:20

Mitral Regurgitation I: Introduction

Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Mitral Stenosis I: Introduction01:22

Mitral Stenosis I: Introduction

Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...